As the first oral selective histone deacetylase (HDAC) inhibitor, chidamide was developed in China and approved for the treatment of R/R PTCL in December 2014 (22). Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.